home > ebr > spring 2013 > boon or bane


Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.


News and Press Releases

BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead

Taipei, Taiwan, February 20th, 2023 / Sciad Newswire / BRIM Biotechnology, Inc. (BRIM, TPEx 6885), a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, is pleased to announce that Andrew Lin was elected as the new Chairman of the Board on 8th February, 2023, and that the new board has appointed Dr. Wen-Chyi Shyu as the company’s new Chief Executive Officer (CEO) from 1st March, 2023. The new leadership team will guide BRIM through what is set to be a transformational year for the company.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement